MBL77 - AN OVERVIEW

Apart from ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and suit adequate to tolerate FCR therapy, should still be superior candidates to the latter, with the gain getting that this remedy could be completed in six months whilst ibrutinib should be taken indefinitely. This feature might be especially precious for non-compliant pati